GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nightstar Therapeutics PLC (NAS:NITE) » Definitions » PS Ratio

Nightstar Therapeutics (Nightstar Therapeutics) PS Ratio : (As of May. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nightstar Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nightstar Therapeutics's share price is $25.41. Nightstar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 was $0.00. Hence, Nightstar Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Nightstar Therapeutics's PS Ratio or its related term are showing as below:

NITE's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.14
* Ranked among companies with meaningful PS Ratio only.

Nightstar Therapeutics's Revenue per Sharefor the three months ended in Mar. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 was $0.00.

Back to Basics: PS Ratio


Nightstar Therapeutics PS Ratio Historical Data

The historical data trend for Nightstar Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nightstar Therapeutics PS Ratio Chart

Nightstar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18
PS Ratio
- - - -

Nightstar Therapeutics Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nightstar Therapeutics's PS Ratio

For the Biotechnology subindustry, Nightstar Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nightstar Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nightstar Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Nightstar Therapeutics's PS Ratio falls into.



Nightstar Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Nightstar Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=25.41/0
=

Nightstar Therapeutics's Share Price of today is $25.41.
Nightstar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Nightstar Therapeutics  (NAS:NITE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Nightstar Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Nightstar Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nightstar Therapeutics (Nightstar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
215 Euston Road, London, GBR, NW1 2BE
Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.
Executives
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Gregory Scott Robinson officer: Chief Scientific Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
James G Mcarthur director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram officer: Chief Financial Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Tuyen Ong officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott M Whitcup director 2525 DUPONT DRIVE, IRVINE CA 92612
Scott D Sandell 10 percent owner
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner